The company strategy is to grow through external outsourcing and alliances with academia and private entities to further develop its proprietary products.
The company wants to develop newly discovered molecules up to the proof of concept stage. High quality candidates will be characterized to the preclinical or first stages of clinical development and could be objects of specific collaborations with private partners. The new IP protected molecules or extracts will be offered to Fully Integrated Pharmaceutical or Cosmetic Companies which can bring them to the market generating revenues (milestones and royalties) for the company.
